Clinigen Group

Clinigen Group is a rapidly-growing specialty pharmaceutical and services company with a unique business model dedicated to delivering the right drug to the right patient at the right time to improve the quality of people’s lives around the world. The Group consists of four synergistic businesses that provide medicines to patients with unmet need through clinical trials, licensed and unlicensed routes: Clinigen Clinical Trial Services (CTS) - The global leader in the specialist supply and management of quality-assured comparator drugs and other commercial medicines for patients in clinical trials. Cinigen is also the leading global patient access specialist working to provide ethical and compliant access to unlicensed medicines for healthcare providers and their patients with high unmet medical need: Idis Managed Access (MA) - Ethically manages early access to unlicensed investigational medicines on behalf of pharmaceutical and biotech companies. Idis Global Access (GA) - Enables access to post-approved medicines in regions where they are not commercially available but where there is a patient need. Clinigen Specialty Pharmaceuticals (SP) - Revitalizes essential hospital only medicines ensuring continuity of supply to hospital pharmacists, doctors and patients.
Company Growth (employees)
Burton Upon Trent, GB
Size (employees)
465 (est)+200%
Clinigen Group was founded in 2010 and is headquartered in Burton upon Trent, GB

Clinigen Group Office Locations

Clinigen Group has an office in Burton upon Trent
Burton upon Trent, GB (HQ)
Clinigen, Pitcairn House, Crown Square, First Avenue

Clinigen Group Data and Metrics

Clinigen Group Financial Metrics

Clinigen Group's revenue was reported to be £339.9 m in FY, 2016 which is a 84% increase from the previous period.

Revenue (FY, 2016)

339.9 m

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

96.1 m

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

13.5 m

Market capitalization (24-Jul-2017)

1.1 b

Closing share price (24-Jul-2017)


Cash (30-Jun-2016)

27.8 m
Clinigen Group's current market capitalization is £1.1 b.
GBPFY, 2013FY, 2014FY, 2015FY, 2016


122.6 m126.6 m184.4 m339.9 m

Revenue growth, %


Cost of goods sold

87.5 m85.4 m130.7 m243.8 m

Gross profit

35.1 m41.2 m53.7 m96.1 m

Gross profit Margin, %


Operating expense total

20.5 m19.7 m44.5 m

Pre tax profit

21.3 m8.3 m15.9 m

Net Income

16.2 m5.7 m13.5 m
GBPFY, 2014FY, 2015FY, 2016


21.8 m27.8 m27.8 m

Accounts Receivable

20.2 m51.4 m57.6 m

Current Assets

51.4 m110 m112.6 m


2.9 m6.6 m13.6 m


50.5 m302.5 m333.7 m

Total Assets

104.9 m419.1 m459.9 m

Accounts Payable

10.3 m48.1 m68.6 m

Current Liabilities

38.6 m158.4 m164.3 m

Total Liabilities

38.6 m214.5 m223.4 m

Retained Earnings

13.7 m3.1 m9.4 m

Total Equity

66.3 m204.6 m236.5 m

Financial Leverage

1.6 x2 x1.9 x
GBPFY, 2014FY, 2015FY, 2016

Cash From Operating Activities

19.3 m13.1 m42.1 m

Cash From Financing Activities

13.8 m181.3 m(12.3 m)

Income Taxes Paid

(5.1 m)(2.6 m)(2.4 m)
Y, 2016

Financial Leverage

1.9 x

Clinigen Group Operating Metrics

Clinigen Group's Units Shipped was reported to be 4 m in FY, 2016
FY, 2016



Units Shipped

3.97 m

Clinigen Group Market Value History

Clinigen Group Revenue Breakdown

Traffic Overview of Clinigen Group

Clinigen Group Online and Social Media Presence

Clinigen Group News and Updates

Clinigen chief executive Peter George to make way for new blood

Peter George, the six-year chief executive of Aim-listed pharmaceuticals company Clinigen, is to leave the helm in November - but he's going out on a high note.  The figures It's been a good week for UK pharma firms. Clinigen has posted a 25 per cent growth in adjusted earnings per share for i…

Clinigen Group Company Life and Culture

You may also be interested in